Myelodysplastic syndrome

Current Opinion in Hematology

Volumn 3, Issue 4, 1996, Pages 297-302

  Forman, Stephen J ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; BIMOLANE; BUSULFAN; CARMUSTINE; CHLORAMBUCIL; CHLORMETHINE; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; LOMUSTINE; MELPHALAN; MITOXANTRONE; PREDNIMUSTINE; RAZOXANE; SEMUSTINE; TENIPOSIDE;

ANALYTIC METHOD; APOPTOSIS; BONE MARROW TRANSPLANTATION; CELL TRANSPLANTATION; CYTOSTASIS; DRUG INDUCED DISEASE; HEMATOPOIESIS; HUMAN; MALIGNANT TRANSFORMATION; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; REVIEW; STEM CELL;

EID: 0030035827     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199603040-00008     Document Type: Review

References (27)

1. Passmore SJ, Hann IM, Stiller CA, Ramani P, Swansbury GJ, Gibbons B, Reeves BR, Chessells JM: Pediatric myelodysplasia: a study of 68 children and a new prognostic scoring system. Blood 1995, 85:1742-1750.
2. Cunningham I, MacCullam SJ, Nicholls MD, Byth K, Hewson JW, Arnold B, Motum PI, Mullligan SP, Crane GG: The myelodysplastic syndromes: an analysis of prognostic factors in 226 cases from a single institution. Br J Haematol 1995, 90:602-606.
3. Boultwood J, Lewis S, Wainscoat J: The 5q-syndrome. Blood 1994, 84:3253-3260.
4. Raghavachar A, Janssen JWG, Schrezenmeier H, Wagner B, Bartram CR, Schulz AS, Hein C, Cowling G, Mubarik A, Testa NG, Dexter M, Hows JM, Marsh JCW: Clonal hematopoiesis as defined by polymorphic X-linked loci occurs infrequently in aplastic anemia. Blood 1995, 86:2938-2947.
5. Pedersen-Bjergaard J, Rowley JD: The balanced and the unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently in malignant transformation. Blood 1994, 83:2780-2786.
6. Traweek T, Slovak ML, Nademanee AP, Brynes RK, Niland JC, Forman SF: Clonal karyotypic hematopoietic cell abnormalities: occurring after autologous bone marrow transplantation for Hodgkln's disease and non-Hodgkin's lymphoma. Blood 1994, 84:957-963.
7. Darrington DL, Vose JM, Anderson JR, Bierman PJ, Bishop MR, Chan WC, Morris ME, Reed EC, Sanger WG, Tarantolo SR, Weisenburger DD, Kessinger A, Armitage JO: Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. J Clin Oncol 1995, 12:2527-2534.
8. Stone RM, Neuberg D, Soiffer R, Takvorian T, Whelan M, Rabinowe SN, Aster JR, Leavitt P, Mauch P, Freedman AS, Nadler LM: Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 1994, 12:2535-2542.
9. Traweek ST, Slovak ML, Nademanee AP, Brynes RK, Niland JC, Forman SJ: Myelodysplasia and acute myeloid leukemia occurring after autologous bone marrow transplantation for lymphoma. Leuk Lymphoma 1996, 20:365-372.
10. Roman-Unfer S, Bitran JD, Hanauer S, Johnson L, Rita D, Booth C, Chen K: Acute myeloid leukemia and myelodysplasia following intensive chemotherapy for breast cancer. Bone Marrow Transplant 1995, 16:163-168.
11. Rohatiner A: Myelodysplasia and acute myelogenous leukemia after myelablative therapy with autologous stem cell transplantation. J Clin Oncol 1994, 12:2521-2523.
12. Roulston D, Anastasi J, Rudinsky R, Nucifora G, Zeleznik-Le N, Rowley JD, McGavran L, Tsuchida M, Hayashi Y: Therapy-related acute leukemia associated with t(11q23) after acute myeloid leukemia with r(8;21): a report of two cases. Blood 1995, 86:3615-3618.
13. Pedersen-Bjergaard J, Pedersen M, Roulston D, Philip P: Different • genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. Blood 1995, 86:3542-3552. Excellent review of the evolution of myelodysplasia and AML after exposure to alkylating agents and those that inhibit topoisomerase II.
14. Kaneko H, Misawa S, Horiike S, Nakai H, Kashima K: TP53 mutations emerge at early phase of myelodysplastic syndrome and are associated with complex chromosomal abnormalities. Blood 1995, 85:2189-2193.
15. Counter CM, Gupta J, Harley CB, Leber B, Bacchetti S: Telomerase activity in normal leukocytes and in hematologic malignancies. Blood 1995, 85:2315-2320.
16. Kaneko H, Horiike S, Inazawa J, Nakai H, Misawa S: Microsatellite instability is an early genetic event in myelodysplastic syndrome. Blood 1995, 86:1236-1237.
17. O'Donnell MR, Long GD, Parker PM, Niland J, Nademanee A, Amylon M, Chao N, Negrin RS, Schmidt GM, Slovak ML, Smith EP, Snyder DS, Stein AS, Traweek T, Blume KG, Forman SF: Busulfan/cyclophosphamide as conditioning regimen for allogeneic bone marrow transplantation for myelodysplasia. J Clin Oncol 1995, 13:2973-2979.
18. Casper J, Camitta B, Truitt R, Baxter-Lowe LA, Bunin N, Lawton C, Murray K, Hunter J, Pietryga D, Garbrecht F, Taylor CK, Drobyski W, Horowitz M, Flomenberg N, Ash R: Unrelated bone marrow transplants for children with leukemia or myelodysplasia. Blood 1995, 85:2354-2363.
19. Delforge M, Demuynck H, Vandenberghe P, Verhoef G, Zachée P, Van •• Duppen V, Marijnen P, Van den Berghe H, Boogaerts MA: Polyclonal primitive hematopoietic progenitors can be detected in mobilized peripheral blood from patients with high-risk myelodysplastic syndromes. Blood 1995, 86:3660-3667. This is an important observation concerning the presence of normal stem cells in the marrow of patients with myelodysplastic syndrome and provides the theoretical basis for using autologous stem cell transplantation in patients who achieve remission after induction therapy.
20. + cells. Blood 1995, 85:194-202.
21. -) in acute myeloid leukemia. Blood 1995, 86:1139-1147.
22. + subpopulations. Blood 1995, 86:2906-2912.
23. Soenen V, Fenaux P, Flactif M, Lepelley P, Lai JL, Cosson A, Preudhomme C: Combined Immunophenotyping and in situ hybridization (FICTION): a rapid method to study cell lineage involvement in myelodysplastic syndromes. Br J Haematol 1991, 90:701-706.
24. Musto P, Scalzulli PR, Carotenuto M: Recombinant erythropoietin for myelodysplastic syndromes. Br J Haematol 1995, 91:243-258.
25. Gordon MS, Nemunaitis J, Huffman R, Paquette RL, Rosenfeld C, Manfreda S, Isaacs R, Nimer SD: A phase I trial of recombinant human interleukin-6 In patients with myelodysplastic syndromes and thrombocytopenia. Blood 1995, 85:3066-3076.
26. Kaushansky K: Thrombopoietin: the primary regulator of platelet • production. Blood 1995, 86:419-431. An excellent review describing the search, identification, and cloning of the gene for thrombopoietin.
27. Raza A, Gezer S, Mundle S, Gao XZ, Alvi S, Borok R, Rifkin S, Iftikhar A, • Shetty V, Parcharidou A, Loew J, Marcus B, Khan Z, Chaney C, Showel J, Gregory S, Preisler H: Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 1995, 86:268-276. An interesting study that attempts to explain the basis for ineffective hematopoiesis seen in myelodysplastic syndrome and suggests a new therapeutic approach that could improve ineffective cell production.